Skip to main content
Daniel Petrylak, MD, Oncology, New Haven, CT

DanielPeterPetrylakMD

Oncology New Haven, CT

Genitourinary Oncology, Hematologic Oncology

Yale University Cancer Center

Dr. Petrylak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Petrylak's full profile

Already have an account?

  • Office

    35 Park Street Np4
    New Haven, CT 06510
    Phone+1 203-200-4822
    Fax+1 203-785-4043

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
  • Jacobi Medical Center/Albert Einstein College of Medicine
    Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1985 - 1988
  • Case Western Reserve University School of Medicine
    Case Western Reserve University School of MedicineClass of 1985

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1985 - 2026
  • CT State Medical License
    CT State Medical License 2012 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
  • America's Top Doctors Castle Connolly, 2006-2014
  • Top Doctors: New York Metro Area Castle Connolly, 2002-2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma  
    Jonathan E Rosenberg, Daniel P Petrylak, The New England Journal of Medicine
  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma  
    Cora N Sternberg, Jeanny B Aragon-Ching, Daniel P Petrylak, Petros Grivas, The New England Journal of Medicine

Lectures

  • EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. 
    2019 ASCO Annual Meeting - 6/1/2019
  • 6th Annual Interdisciplinary Prostate Cancer Congress® 
    Physicians' Education Resource, LLC , Physicians' Education Resource, LLC, New York, New York - 3/16/2013

Press Mentions

  • Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in Cisplatin-Ineligible Patients with mUC Progressing to Previous Treatment with ICI
    Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in Cisplatin-Ineligible Patients with mUC Progressing to Previous Treatment with ICISeptember 16th, 2024
  • Various Cancer Treatment Drugs Experiencing Nationwide Shortage
    Various Cancer Treatment Drugs Experiencing Nationwide ShortageMay 22nd, 2023
  • BCG Response in Bladder Cancer Cases Linked to Tumor Microbiome
    BCG Response in Bladder Cancer Cases Linked to Tumor MicrobiomeMay 16th, 2023
  • Join now to see all

Grant Support

  • Columbia University Southwest Oncology Group ProgramNational Cancer Institute2003

Professional Memberships

Other Languages

  • French